Squarepoint
RCUS icon

Squarepoint’s Arcus Biosciences RCUS Stock Holding History

Squarepoint’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.44M Buy
+66,674
New +$1.44M ﹤0.01% 2450
2025
Q3 		– Sell
-199,649
Closed -$1.63M – 4880
2025
Q2 		$1.63M Buy
199,649
+123,938
+164% +$1.06M ﹤0.01% 2254
2025
Q1 		$594K Buy
+75,711
New +$878K ﹤0.01% 3137
2024
Q3 		– Sell
-16,700
Closed -$254K – 4595
2024
Q2 		$254K Buy
+16,700
New +$270K ﹤0.01% 3519
2024
Q1 		– Sell
-32,569
Closed -$622K – 4503
2023
Q4 		$622K Sell
32,569
-214,211
-87% -$3.42M ﹤0.01% 2858
2023
Q3 		$4.43M Sell
246,780
-27,668
-10% -$556K 0.01% 1253
2023
Q2 		$5.57M Buy
274,448
+186,862
+213% +$3.56M 0.02% 1016
2023
Q1 		$1.6M Buy
87,586
+53,961
+160% +$1.03M 0.01% 1572
2022
Q4 		$695K Buy
33,625
+17,527
+109% +$482K ﹤0.01% 2076
2022
Q3 		$421K Sell
16,098
-88,417
-85% -$2.34M ﹤0.01% 2284
2022
Q2 		$2.65M Buy
104,515
+2,819
+3% +$69K 0.01% 1024
2022
Q1 		$3.21M Buy
101,696
+84,281
+484% +$2.82M 0.01% 892
2021
Q4 		$705K Buy
+17,415
New +$676K ﹤0.01% 1922
2021
Q2 		– Sell
-30,473
Closed -$856K – 3614
2021
Q1 		$856K Sell
30,473
-52,975
-63% -$1.84M 0.01% 1633
2020
Q4 		$2.17M Sell
83,448
-31,715
-28% -$768K 0.02% 897
2020
Q3 		$1.97M Sell
115,163
-44,636
-28% -$997K 0.03% 653
2020
Q2 		$3.95M Buy
+159,799
New +$4.31M 0.06% 408
2020
Q1 		– Sell
-23,911
Closed -$242K – 2391
2019
Q4 		$242K Buy
+23,911
New +$201K ﹤0.01% 2136

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Squarepoint's RCUS Position: Q1 2026 in Review

Squarepoint opened a new position in Arcus Biosciences (RCUS) in Q1 2026: 66,674 shares worth $1.44M. The stake represents ﹤0.01% of the portfolio and ranks #2450 among its holdings. This is a return to the name: Squarepoint previously reported a position in RCUS as recently as Q2 2025.

Squarepoint first reported a position in RCUS in Q4 2019 and has held it in 18 quarters since. The position peaked at $5.57M in Q2 2023. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Squarepoint held 66,674 shares of Arcus Biosciences worth $1.44M as of Q1 2026.
  • Arcus Biosciences was a new Squarepoint position in Q1 2026.
  • Arcus Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2450 holding.
  • Squarepoint first reported a position in Arcus Biosciences in Q4 2019 and has held it in 18 quarters since.
  • Squarepoint's Arcus Biosciences position peaked at $5.57M in Q2 2023.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.